Status:
RECRUITING
Xenografts Development from Surgical Tumor Samples of Patients with Triple Negative or Luminal B Breast Cancer
Lead Sponsor:
Centre Jean Perrin
Conditions:
Breast Cancer Female
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the real...
Eligibility Criteria
Inclusion
- ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
- Signature of the participation consent to the study,
- Affiliation to a social security scheme
- Major woman with:
- metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of neoadjuvant treatment
- metaplastic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, treated by primary surgery with a tumor size of at least 15 mm on the specimen.
- an inflammatory TN breast cancer (T4d), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
- non-metaplastic or inflammatory TN breast cancer, histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
- Luminal B breast cancer (LB), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment.
- histologically proven metastatic TN or metastatic breast cancer with an operable metastasis whose residual size, after chemotherapy, is at least 10 mm on the specimen. Residual metastasis will be at least 15 mm on imaging.
- Patients in a metastatic situation can be included regardless of the therapeutic line.
Exclusion
- Pregnant woman
- Patient deprived of liberty by court or administrative decision
- In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy
- Refusal to participate in the study
Key Trial Info
Start Date :
November 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT04133077
Start Date
November 19 2021
End Date
May 31 2026
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean PERRIN
Clermont-Ferrand, Puy-de-Dôme, France, 63011